August 4, 2020 Licensing, IP, and Legal

The United States Court of Appeals for the Federal Circuit Affirms that 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the The United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld... Read more

May 4, 2020 Clinical Research/Diagn. Life Science Tools

Bio-Rad Receives FDA Emergency Use Authorization for Droplet Digital PCR SARS-CoV-2 Test Kit

Date: 05/04/2020 HERCULES, Calif. –Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs... Read more

April 7, 2020 Clinical Research/Diagn. Product Launch

Bio-Rad Announces the Launch of a Serology Assay to Detect Coronavirus (COVID-19) Antibodies

Date: 04/07/2020 HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company is launching a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. Preliminary performance of the assay has been established and the... Read more

March 12, 2020 Clinical Research/Diagn. Product Launch

Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing

Date: 03/12/2020 HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that through its Exact Diagnostics product line Bio-Rad has launched a SARS CoV-2 Standard to support laboratory assay validation of coronavirus (COVID-19) testing. Bio-Rad is providing the SARS CoV-2 Standard to... Read more

January 6, 2020 Clinical Research/Diagn. Life Science Tools PR/Corporate

Bio-Rad Appoints Dara Grantham Wright Executive Vice President and Clinical Diagnostics Group President

Date: 01/06/2020 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dara Grantham Wright as Executive Vice President and President of the Clinical Diagnostics Group, effective January 1, 2020. She takes the place of John Hertia who retired from this... Read more

September 11, 2019 Licensing, IP, and Legal Life Science Tools

Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement

Date: 09/11/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has filed a patent infringement suit against 10X Genomics, Inc. in the United States District Court for the District of Delaware. In the lawsuit Bio-Rad asserts that 10X Genomics infringes... Read more

July 24, 2019 Licensing, IP, and Legal

Delaware District Court Grants Bio-Rad’s Motion for Permanent Injunction Against 10X Genomics

ate: 07/24/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announces that today the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and... Read more

June 27, 2019 PR/Corporate

Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The outlook was changed to stable from positive. According to Moody’s, the upgrade reflects recent... Read more

April 22, 2019 PR/Corporate

Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer

Date: 04/22/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. In this role, Dr. Last is responsible for all operating functions of the company... Read more

April 8, 2019 Clinical Research/Diagn. Licensing, IP, and Legal

Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

Date: 04/08/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad’s IH-500, an automated random access system for blood typing and screening. The IH-500 system was designed for small-... Read more